Stryker Puts $400 Million Into CMR Surgical With Versius Cleared for One Procedure

Stryker will put about $400 million into CMR Surgical, the Cambridge, England maker of the Versius soft-tissue robot, and holds an exclusive option to buy the rest of the company. The catch is that Versius Plus has one cleared U.S. use so far: gallbladder removal.

Stryker (NYSE:SYK) and CMR announced the deal on Oct. 12. The $400 million (£300 million) is a preferred equity investment, subject to customary closing conditions and regulatory approvals. Stryker also becomes the exclusive U.S. sales agent for the Versius portfolio, while CMR keeps development and sales outside the United States. Neither company disclosed a valuation, the option's terms or the preferred stock's conversion rights.

What the FDA has cleared, and what Stryker's release implies

The release says CMR's second-generation robot "supports a broad range of soft tissue procedures." The FDA's view is narrower. CMR's own announcement of Dec. 16, 2025 says the agency granted 510(k) clearance for Versius Plus for cholecystectomy, the surgical removal of the gallbladder, after the first-generation Versius received De Novo authorization in October 2024. CMR said it is pursuing additional U.S. indications and expected to begin U.S. commercialisation in 2026.

The number that matters here is not $400 million but one: one cleared indication. A hospital buying a surgical robot spends against a procedure mix, and a system cleared only for one operation can be used only for that one in the United States. Each added clearance widens the pool of cases a Versius can be scheduled for. The deal pays for that wait.

Item	Figure	Source
Stryker investment	About $400 million (£300 million), preferred equity	Stryker release, Oct. 12
Acquisition option	100% of CMR's equity	Stryker release
U.S. clearance	Versius Plus 510(k), cholecystectomy	CMR, Dec. 16, 2025
Procedures outside the U.S.	Over 40,000	CMR, Dec. 16, 2025

The 40,000-procedure claim

CMR said in December that its platforms have completed over 40,000 procedures outside the United States, which it says makes them the second most used soft-tissue robots in the world. That is the company's own claim, and CMR does not name the leading platform, the countries, the hospitals or the period. It is also a count of procedures, not of robots installed; neither CMR nor Stryker gives an installed base.

Divide the investment by the procedure count and the result is $10,000 a procedure. That figure is a crude denominator, not a valuation: the cash buys a U.S. launch, not a history. What it does show is the scale of the bet against a base with no U.S. track record, and why the missing disclosures matter: with no installed-base count and no price per system, an outside reader cannot test whether $400 million is a high or low entry fee for the segment, or tell how much of the money is for the robot and how much for the option.

How the sales arrangement is split

Stryker's role is sales agent. The release does not say who books revenue, who services the robots or who employs the U.S. clinical staff. Bioxconomy's coverage says the money funds CMR's "CMR 3.0" strategy, which covers the Versius Plus roadmap, global expansion and what the company calls its move toward intelligent surgery. CMR chief executive Massimiliano Colella said in the release that Stryker's investment "will give us additional strength to accelerate innovation," and that Andy Pierce, Stryker's group president for Medsurg and Neurotechnology, will join CMR's board.

Pierce said Stryker has "evaluated the segment carefully for years." The release calls soft-tissue robotics "a high-growth adjacency" to Stryker's endoscopy and visualization business. Stryker has not said what it would pay if it exercises the option.

Where the robot would be used

Stryker's Pierce said the company chose Versius to help providers "grow robotic-assisted surgery adoption across a broad range of procedures in hospitals and ASCs", the last being ambulatory surgery centres, where patients go home the same day. The release describes a "modular architecture" meant to fit existing operating room workflows. It offers no price, no footprint and no per-case cost, which are the three things a surgery centre's finance office would ask for first.

Bioxconomy quotes Colella saying the alliance "provides additional financial strength and commercial reach" and gives Versius Plus "a significantly stronger route to market in the US." Taken at their word, the two companies are describing a distribution gap, not a technology gap. CMR has a cleared robot; what it lacked in the United States was a sales force and balance sheet.

The timeline so far

The clearances arrived 14 months apart: De Novo authorization for the first Versius in October 2024, then 510(k) clearance for Versius Plus on Dec. 16, 2025, for the same gallbladder indication. CMR said then that it expected to begin U.S. commercialisation in 2026. Stryker's Oct. 12 release does not say whether a Versius Plus has been sold in the United States, so the first U.S. cases are not part of the record yet.

What would change my read

Three disclosures would turn this from a distribution agreement into a measurable business: a second U.S. indication, a count of Versius Plus systems installed at U.S. hospitals, and the option price. The release gives no date for any of them, and ties the closing to regulatory approvals without naming a month.

For other cases where a robot maker's claim needs a denominator before it means anything, see Agility's Digit 5 charging claim and Waymo's Toronto timetable.